产品介绍 评论(0)
物种
Human分子别名
Dihydrofolate reductase, EC:1.5.1.3, DHFRAccession
P00374表达序列
Protein sequence (P00374, Met1-Asp187, with C-His tag) MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND
表达宿主
E.coli分子量
Predicted MW: 23.1 kDa Observed MW: 24 kDa
纯度
>95% by SDS-PAGE内毒素含量
<1EU/μg标记
Unconjugated标签
with C-His tag性状
Lyophilized Powder缓冲体系
Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4.
溶解方法
Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation.储存条件
12 months from date of receipt, -20 to -70 °C as supplied.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
1 week, 2 to 8 °C under sterile conditions after reconstitution.
Please avoid repeated freeze-thaw cycles.
Dihydrofolate reductase, or DHFR, is an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, using NADPH as an electron donor, which can be converted to the kinds of tetrahydrofolate cofactors used in one-carbon transfer chemistry. DHFR mutations cause dihydrofolate reductase deficiency, a rare autosomal recessive inborn error of folate metabolism that results in megaloblastic anemia, pancytopenia and severe cerebral folate deficiency. These issues can be overcome by supplementation with a reduced form of folate, usually folinic acid. DHFR is an attractive pharmaceutical target for inhibition due to its pivotal role in DNA precursor (thymine) synthesis. Trimethoprim, an antibiotic, inhibits bacterial DHFR while methotrexate, a chemotherapy agent, inhibits mammalian DHFR.
电泳
2μg(R: reducing conditions)







评论(0)